Silent familial isolated pituitary adenomas: histopathological and clinical case report.

Department of Human and Hereditary Pathology, S. Matteo IRCCS Foundation, University of Pavia, Pavia, Italy.
Endocrine Pathology (Impact Factor: 1.6). 04/2008; 19(1):40-6. DOI: 10.1007/s12022-008-9018-2
Source: PubMed

ABSTRACT Familial isolated pituitary adenoma (FIPA) is a rare condition independent of Carney Complex or MEN1. An international multicenter study recently described 28 nonfunctioning pituitary adenomas in 26 families with only two homogeneous nonsecreting phenotype families consistent of silent GH and silent gonadotroph adenomas, respectively. We present the clinical, genetic, and morphological analysis of two silent pituitary adenomas occurring in a man and his daughter, and discuss the differential diagnosis associated with their histological, immunohistochemical, and ultrastructural features. The patients developed invasive nonsecreting macroadenomas manifesting only with compressive symptoms. Genetic analysis in the father showed no MEN-1 germ-line mutation. Tissue samples obtained after paraseptal trans-sphenoidal surgery were studied by immunohistochemistry for adenohypophyseal hormones, low molecular weight cytokeratins (CAM 5.2), proliferation markers, and anterior pituitary transcription factors (Pit-1 and SF-1) and by electron microscopy for secretory granules. The clinical, histological, and immunohistochemical features of the lesions posed a differential diagnosis between a null cell adenoma and a silent corticotroph adenoma (Type II); on the basis of immunohistochemical stains for cytokeratin and adenohypophysis cell lineage markers, tumor behavior and ultrastructural studies we concluded for the second. The reported cases represent an as yet undescribed example of homogeneous family with silent corticotroph adenomas (Type II). Our observations support the trend for more aggressive behavior in nonsecreting FIPAs as compared with sporadic adenomas.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Pituitary adenomas are being recognized and diagnosed with increasing frequency. One of the most common forms of pituitary lesion is the clinically non-functioning pituitary adenoma (NFPA), which is often diagnosed incidentally. The vast majority of pituitary adenomas are sporadic, but familial adenomas can occur in the multiple pituitary adenoma type 1 syndrome, in Carney complex or in familial isolated pituitary adenoma. Distinguishing NFPA from prolactinomas can occasionally cause a differential diagnostic problem due to the 'stalk effect'. NFPA often show hormone synthesis on tissue immunostaining without causing clinical symptoms. Most often these are silent gonadotroph adenomas, with silent corticotroph or somatotroph adenomas occurring less frequently. It is unclear why these silent adenomas do not release hormones at a clinically recognizable level, although it is probable that there is a continuum between fully functional and completely silent adenomas. Another intriguing feature of NFPAs is the lack of clinical response to somatostatin analogues, despite the presence of somatostatin receptors and an often good response in the in vitro setting. Temozolomide has been successfully used for the treatment of a few aggressive pituitary adenomas, and the response to this drug could be influenced by the expression of the DNA repair enzyme O-6-methylguanine DNA methyltransferase. The early diagnosis, prediction of long-term outcome and treatment of NFPAs remain a challenge for endocrinologists.
    Hormone Research 05/2009; 71 Suppl 2:123-30. · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Molecular alterations in endocrine tumors can be related to genetic syndromes or can be somatic mutations that are restricted to tumor tissues. Tumors associated with genetic syndromes have been described for all endocrine organs and include medullary thyroid carcinoma, parathyroid tumors, pituitary adenomas, adrenal cortical tumors, and pheochromocytomas. The endocrine syndromes are discussed in detail, with particular attention to mutational analysis. In terms of somatic mutations, the most advanced understanding is for thyroid and parathyroid lesions, where established markers are making their way slowly into clinical practice. Somatic mutations for endocrine tumors are also discussed, with an emphasis on testing that has clinical diagnostic and therapeutic implications. KeywordsPapillary carcinoma–Follicular carcinoma–Medullary carcinoma–Multiple endocrine neoplasia syndrome–BRAF mutation–RAS mutation–RET/PTC translocation–RET mutation–Parathyroid adenoma–Parathyroid carcinoma–Hyperparathyroidism-jaw tumor syndrome–HRPT2 gene–Pituitary adenoma–Carney complex–McCune-Albright syndrome–Adrenal cortical adenoma–Adrenal cortical carcinoma–Beckwith-Wiedemann syndrome–Li-Fraumeni syndrome–Pheochromocytoma–Von Hippel-Lindau syndrome–Neurofibromatosis–Familial paragangliomatosis syndrome
    03/2010: pages 221-234;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pituitary adenomas are benign intracranial neoplasms and clinically apparent pituitary adenomas have a prevalence of approximately 1:1,000 individuals. They usually arise sporadically, but familial pituitary adenomas comprise about 5% of all cases, more than half of which include multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). The other half is represented by familial isolated pituitary adenomas (FIPA), a clinical entity described in the late 1990s. Recently, interest has been focused on the genetic pathophysiology of familial pituitary adenomas. MEN1 is due to mutations in MEN1 gene. CNC is related to PRKAR1A mutations and still unknown disruptions on 2p16. Mutations of CDKN1B in MEN1-like patients without MEN1 mutations allowed the differentiation of the condition as MEN4. About 15% of FIPA kindreds are associated with aryl hydrocarbon receptor-interacting protein (AIP) gene mutations, which suggests that this is a genetically heterogeneous condition. Overall, familial pituitary adenomas represent a small proportion of pituitary tumors, but are particularly significant as affected individuals may be younger, and adenomas may be relatively difficult to treat. KeywordsMultiple endocrine neoplasia type 1-MEN4-Carney complex-Familial isolated pituitary adenomas
    12/2010: pages 137-150;

Full-text (2 Sources)

Available from
Jun 2, 2014